Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 9/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | SOD1 | P00441 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6158606 | 0.87 | CHRNA7 (0.43) | MAOBALDH1A1KDM4E | |
| SCHEMBL1284438 | 0.86 | MAOB (0.45) | MAOBALDH1A1KDM4ELMNARAB9A | |
| SCHEMBL5922464 | 0.85 | ALDH1A1 (0.47) | MAOBALDH1A1KDM4ELMNARAB9A | |
| SCHEMBL3636719 | 0.82 | MAOB (0.55) | MAOBALDH1A1KDM4ELMNARAB9A | |
| SCHEMBL18529849 | 0.82 | SOD1 (0.35) | SOD1 | |
| SCHEMBL4665393 | 0.82 | LMNA (0.40) | ALDH1A1KDM4ELMNARAB9AHTT | |
| SCHEMBL6294536 | 0.81 | MAOB (0.50) | MAOBALDH1A1KDM4ELMNARAB9A | |
| SCHEMBL3571947 | 0.80 | APP (0.38) | MAOBKMT2A | |
| SCHEMBL31173236 | 0.79 | MAOB (0.51) | MAOBALDH1A1KDM4ELMNARAB9A | |
| SCHEMBL27075523 | 0.79 | MAOB (0.51) | MAOBALDH1A1KDM4ELMNARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190010173-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF CATHEPSINS | MATEON THERAPEUTICS, INC. (US) | 2019-01-10 | — | — | US | claimed |
| WO-2017030983-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF CATHEPSINS | MATEON THERAPEUTICS, INC. (US) | 2017-02-23 | — | — | WO | claimed |
| US-20230390281-A1 | OPIOID FOR USE TO REDUCE AND/OR DRUG ADDICTION | DMK PHARMACEUTICALS CORPORATION | 2023-12-07 | — | — | US | disclosed |
| US-11779581-B2 | Opioid for use to reduce and/or treat drug addiction | DMK PHARMACEUTICALS CORPORATION (US) | 2023-10-10 | — | — | US | disclosed |
| US-20220226312-A1 | OPIOID FOR USE TO REDUCE AND/OR TREAT DRUG ADDICTION | DMK PHARMACEUTICALS CORPORATION | 2022-07-21 | — | — | US | disclosed |
| US-11246865-B2 | Opioid for use to reduce and/or treat drug addiction | VERSI GROUP, LLC (US) | 2022-02-15 | — | — | US | disclosed |
| US-20210322362-A1 | ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS | NOVARTIS AG (CH) | 2021-10-21 | — | — | US | disclosed |
| US-20210220349-A1 | DELTA OPIOID AGONIST, MU OPIOID ANTAGONIST COMPOSITIONS AND METHODS FOR TREATING PARKINSONS DISEASE | DMK PHARMACEUTICALS CORPORATION | 2021-07-22 | — | — | US | disclosed |
| US-10973815-B2 | Delta opioid agonist mu opioid antagonist compositions and methods for treating Parkinsons disease | VERSI GROUP, LLC (US) | 2021-04-13 | — | — | US | disclosed |
| US-20200121674-A1 | AN OPIOID FOR USE TO REDUCE AND/OR TREAT DRUG ADDICTION | DMK PHARMACEUTICALS CORPORATION | 2020-04-23 | — | — | US | disclosed |
| US-20190038620-A1 | DELTA OPIOID AGONIST MU OPIOID ANTAGONIST COMPOSITIONS AND METHODS FOR TREATING PARKINSONS DISEASE | DMK PHARMACEUTICALS CORPORATION | 2019-02-07 | — | — | US | disclosed |
| US-20020049217-A1 | Inhibitors of prenyl-protein transferase | MERCK SHARP & DOHME CORP. | 2002-04-25 | — | — | US | disclosed |
| WO-2001051126-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 2001-07-19 | — | — | WO | disclosed |
| EP-0780369-B1 | 1-Phenyl-2-dimethylaminomethyl-cyclohexan-1-ol derivatives as pharmaceutical agents | GRUENENTHAL GMBH (DE) | 2000-01-19 | — | — | EP | disclosed |
| US-5854249-A | Opioid diarylmethylpiperazines and piperidines | DELTA PHARMACEUTICALS, INC. (US) | 1998-12-29 | — | — | US | disclosed |
| US-5801201-A | 1-phenyl-2-dimenthylaminomethyl-cyclohexan-1-ol compounds as pharmaceutical active ingredients | GRUENENTHAL GMBH (DE) | 1998-09-01 | — | — | US | disclosed |
| US-5658908-A | RECEPTOR BINDING SPECIES FOR MEDIATING ANALGESIA, COMBATTING DRUG ADDICTION, DRUG OVERDOSE | DELTA PHARMACEUTICALS, INC. (US) | 1997-08-19 | — | — | US | disclosed |
| EP-0780369-A1 | 1-Phenyl-2-dimethylaminomethyl-cyclohexan-1-ol derivatives as pharmaceutical agents | Grünenthal GmbH (DE) | 1997-06-25 | — | — | EP | disclosed |
| EP-0649414-A1 | OPIOID DIARYLMETHYLPIPERAZINES AND PIPERIDINES | THE WELLCOME FOUNDATION LIMITED (GB) | 1995-04-26 | — | — | EP | disclosed |
| WO-1993015062-A1 | OPIOID DIARYLMETHYLPIPERAZINES AND PIPERIDINES | THE WELLCOME FOUNDATION LIMITED (GB) | 1993-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200121674-A1 | AN OPIOID FOR USE TO REDUCE AND/OR TREAT DRUG ADDICTION | OPRM1, OPRK1, OPRD1 | MAOB 414/4885ALDH1A1 56/4885KDM4E 714/4885 |
| US-10973815-B2 | Delta opioid agonist mu opioid antagonist compositions and methods for treating Parkinsons disease | OPRD1, OPRK1, OPRM1 | MAOB 99/4885ALDH1A1 2024/4885KDM4E 2180/4885 |
| US-11779581-B2 | Opioid for use to reduce and/or treat drug addiction | OPRM1, OPRK1, OPRD1 | MAOB 359/4885ALDH1A1 59/4885KDM4E 811/4885 |
| US-20210322362-A1 | ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS | IRF3, EIF2AK2, MAVS | MAOB 2421/4885ALDH1A1 1444/4885KDM4E 3439/4885 |
| US-20020049217-A1 | Inhibitors of prenyl-protein transferase | FNTA, KRAS, NRAS | MAOB 4531/4885ALDH1A1 3836/4885KDM4E 3409/4885 |
| US-20190038620-A1 | DELTA OPIOID AGONIST MU OPIOID ANTAGONIST COMPOSITIONS AND METHODS FOR TREATING PARKINSONS DISEASE | OPRD1, OPRK1, OPRM1 | MAOB 99/4885ALDH1A1 2024/4885KDM4E 2180/4885 |
| US-20230390281-A1 | OPIOID FOR USE TO REDUCE AND/OR DRUG ADDICTION | OPRM1, OPRK1, OPRD1 | MAOB 355/4885ALDH1A1 55/4885KDM4E 884/4885 |
| US-20190010173-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF CATHEPSINS | CTSS, CTSB, CTSK | MAOB 1059/4885ALDH1A1 2840/4885KDM4E 4336/4885 |
| US-20220226312-A1 | OPIOID FOR USE TO REDUCE AND/OR TREAT DRUG ADDICTION | OPRM1, OPRK1, OPRD1 | MAOB 359/4885ALDH1A1 59/4885KDM4E 811/4885 |
| US-20210220349-A1 | DELTA OPIOID AGONIST, MU OPIOID ANTAGONIST COMPOSITIONS AND METHODS FOR TREATING PARKINSONS DISEASE | OPRD1, OPRK1, OPRM1 | MAOB 94/4885ALDH1A1 2158/4885KDM4E 2348/4885 |
| US-11246865-B2 | Opioid for use to reduce and/or treat drug addiction | OPRM1, OPRK1, OPRD1 | MAOB 359/4885ALDH1A1 59/4885KDM4E 811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.